Member Info for Justaride69

You do know that they are going to run out of money by the end of the year without raising more cash, exactly the same as last year before they raised?

So, they voted on all the usual stuff the same as any AGM, then....Whoop Whoop, go team, what an amazing show...and they used "corporate words" and talked about creating value for their shareholders (especially those buying into the next private offering), this is a board that mean business.....Mind Blown by todays totally expected RNS.

I didnt realise that we are only allowed to act as if everything in the world is rosy?

This is a forum not an echo chamber.

Not here to entertain you and i will buy and sell as and when i like the same as iv;e always done (and i have done pretty good from awakn and solvonis so far)

You don't like my comments, then don't read them it really makes no difference to me.

You can use your voice here to add anything of value...or not as the case may be.

Thats what a forum is for not sure why you think it being a popularity contest is important.

Sorry if you have no interest in doing any real DD for yourself, your money and your choice how you "invest" and certainly not interested or bothered about telling anyone else what they should do with their shares.

Apologies for not spouting mindless platitudes.

We live in the real world not some manufactured fantasy one.

"the extra staff being taken on to increase recruitment into the 280n 001 programme did no one question if these people were working for free until 2028? "

Has recruitment been pushed back deeper into 2027 then, i missed that release, to my knowledge the readout is due in 2028 so presumably they wont need staff for recruitment from the beginning of 2027?

"Solvonis is known for conserving its cash, as per the RNS from them it can conserve even more if required to stretch funds into 2027"

I think you either deliberately or not misinterpreted or misquoted this rns,?

One thing that Solvonis has been known for over the last year is the already MASSIVE dilution of 196% increase of outstanding shares...

it was basically stating the need to raise funds imminently and adding that at the worst they could streamline and eke out the remaining reserve of cash into 2027 if no investment was found before.

At least we can look forward to a reverse split sometime in the future when they want to go for Nasdaq and will need to raise again.

"the BOD have been very quiet lately"

I take it this comment was about the fact that we were promised rns for last quarter which never appeared and neither did any updates about them, which will always unnerve any investor.

No further along the path to bridging to spravato, Which explains why the promised RNS never materalised last quarter, exactly the same as the loan application.

I am sure the BOD, exactly the same as any other board are working hard for their shareholders (or at least we hope so) but a little more engagement along with answering emails always helps, especially when promised updates have not appeared.....

You do realise that the new 75% of shares to be issued WILL BE VERY DILUTIVE, so your comment about "non dilutive funding" is either deliberately misleading or outright wrong.

The best we can hope for is that the shares have not been discounted from the daily sp.

You certainly dont need to be a genius to work out the effect on the sp when the share count has just been dramatically and majorly increased by up to 75%?

lets be honest here the engagement form the BOD this quarter has been pretty abysmal and I am personally disappointed.

Looking like the only person smiling will be the mystery 5million seller as he gets to cash out then buy back in again at a massive discount, wash, rinse and repeat.

Personally have never followed the "crossed finger" approach to investing.

Much prefer numbers.

still slightly amazed that many posters here seem even slightly surprised at the thought that SVNS have to raise funds before their cash runs out.

I still believe in this company and am happy that they can find private investors to keep the company moving forward and fortunately did take profis in the mid 30's knowing full well that a raise was practically inevitable.

Its a shame that the rns we were told to look for last quarter never materialised but if there are any near term catalysts that you are expecting in the next 2 weeks then feel free to share why you think that would change any of the voting resolutions?

The listed resolutions to be voted on are below all the usual annual votes to appoint auditors and reelect directors....Not really sure what "updates" you are expecting from an AGM?

and once you've read it through, any thoughts that they are trying to "pull a rabbit out of a hat" disappear, unless the "Special Resolution" has floppy ears and whiskers?

The Notice of Annual General Meeting released via the London Stock Exchange outlines the standard suite of ordinary and special proxy resolutions.

Because the full circular is posted directly to registered shareholders, the voting package covers several routine and strategic mandates typical for an LSE Main Market biopharmaceutical company:

Ordinary Resolutions (Requires >50% Approval)Receiving the Annual Report:

Formally accepting the audited financial statements and directors' reports for the fiscal year ended 31 December 2025.Re-election of Directors:

Voting on the scheduled rotation or confirmation of existing board members to maintain corporate governance continuity.

Auditor Appointment:

Re-appointing the company’s independent auditors and granting the directors the authority to fix their remuneration.

Authority to Allot Shares:

Granting directors the base legal framework to issue new ordinary shares up to a designated nominal amount without immediately needing a full shareholder meeting.

⚡ Special Resolutions (Requires >75% Approval)Disapplication of Pre-emption Rights:

Waiving shareholders' first right of refusal for new equity issuance.

This is critical for junior biotech firms like Solvonis to quickly execute private placements or clinical funding rounds without administrative delays.

Get ready for dilution the price isn't going up this month, that's for sure.

Not silence.

First the AGM then the raise...

Capital and Financing Authorities (Crucial for Cash Raise)

Given that Solvonis’s cash runway only extends to the end of 2026, the meeting will feature standard but critical financing resolutions to lay the groundwork for their next capital raise:

Authority to Allot Shares:

Granting the directors the legal authority under Section 551 of the Companies Act 2006 to issue new ordinary shares up to a specified nominal amount without requiring further shareholder approval meetings

Disapplication of Pre-emption Rights:

A special resolution allowing directors to allot these new shares for cash directly to institutional investors or partners, bypassing the lengthy and restrictive legal requirement to offer them to existing shareholders first.

Many people that were here pre solvonis are sitting on 100% or more gains at 20+

Profit taking in March/the end of the financial year has never been a new thing.....https://www.lse.co.uk/ShareChat.html?ShareTicker=SVNS&thread=898DBEFD-D121-4000-BE61-41B7EBE498C2&reply=true#posting-rules

Not sure about scars, i was there when AWAKN almost got delisted from NEO, months before the buyout and due to my trust, DD and conviction in Prof Nutt (who I am fortunate to have been in the same room as a few times though never to hear him talking about the company specifically) and the company management style, experience and expertise, I have done pretty well this far and still here for the long run.

Sure, I still see no similarities or correlation between them and Solvonis whatsoever.

But it has been a disappointing quarter when it comes to news releases so I understand why throwing around big numbers and pointless name dropped companies can help keep up the interest amongst unsophisticated followers here.

I am confused here, What does Generate have to do with Solvonis that makes it important enough to get a headline on this forum?

Are you shilling?

Not sure why you are talking about Mindmed as a peer, do you even know what the companys name or ticker is, yet alone anything about its pipeline?....Not sure why anyone would consider them peers, unless they have done zero research or DD

And then dropped from its 10.80 high back to 9.2 and falling in less than 24 hrs...your point is?

Apart from appearing to be here trying to hype another stock, what exactly do you think that this has to do with Solvonis?

I have been in this company since awakn days on Neo and believe in them but posts like this don't really help....

By Mindmed I take it that you are talking about Definium (DFTX ticker on Nasdaq) and your apparent lack of DD/knowledge of that obviously rules you out of talking about their pipelines and trials.

Atai and its pipelines (including their share in compass pathways) is a totally different beast and

and as for Abbivie...are you serious to compare them in the same breath....what are the 10 biggest similarities that you see....or even 3?

they invested more than $63 billion in research over the last 10+ years and their revenues have long been something that most pharma companies would dream about.

I understand your enthusiasm but lets try to keep it anchored in reality rather than baseless hyperbole , that way any serious investors with a fondness for their own DD will take the forum here more seriously?

[LINK REMOVED]

CREST | Nominee Acc. Holdings (LONGS – long-term retail investors) → 3,117,340,802 shares (52.76%).

I think that with a little research you will find that CREST is counted towards thre free shares so the true percentage is not 7.7% but is closer to 55%

altough you class them as "long term retail investors" i am not sure why you think that they dont contribute to the free shares?